Skip to main content
AmigoFish

Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces

From BiotechTV - News · · 14 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for.

Back to BiotechTV - News · Report a problem